Skip to main content
2022 Guide to Patient Support Services

GlaxoSmithKline

2022 Oncology Guide to Patient Support Services

GlaxoSmithKline: Together with GSK Oncology Patient Support Services

844-447-5662

GlaxoSmithKline (GSK), through its Together with GSK Oncology program, provides claims assistance, access, and reimbursement support services for its oncology drugs (Table).

Together with GSK Oncology

Commercial Co-pay Assistance Program

Eligible patients with commercial insurance may receive assistance with their out-of-pocket expenses for Zejula, Blenrep, or Jemperli, including up to $100 per administration for intravenous drugs, for a total annual limit of $26,000. Patients may be eligible if they:

  • Have a commercial medical or prescription insurance plan
  • Are uninsured
  • Reside in the United States, including the District of Columbia, Puerto Rico, or the US Virgin Islands
  • Are not eligible for or enrolled in a government-funded program.

Patient Assistance Program

Uninsured patients who meet eligibility requirements may access medication free of charge through GSK’s Patient Assistance Program. Medicare patients who meet specific program requirements may also be eligible for this program.

To qualify for the Zejula, Blenrep, or Jemperli Patient Assistance Program, a patient must:

  • Live in the United States, the District of Columbia, Puerto Rico, or the US Virgin Islands
  • Meet one of the following criteria:
    • Be uninsured
    • Have private commercial insurance but have no coverage (medical or pharmacy) for the product, as demonstrated to the program through the defined Appeals Process criteria
    • Not be currently receiving prescription drug coverage through a government program (excluding Medicare), which includes Medicaid, Veterans Affairs, Department of Defense, or TRICARE benefits
    • Not be eligible for Puerto Rico’s government health plan Mi Salud, or have applied and been denied
    • Meet certain income eligibility requirements.

For assistance with the Zejula, Blenrep, or Jemperli Patient Assistance Program, please call Together with GSK Oncology at 844-447-5662. Click here to review program terms and conditions.

Ophthalmology Support Services

Blenrep is available only through the Blenrep REMS (Risk Evaluation and Mitigation Strategy), a restricted distribution program to help manage the risk of ocular toxicity. The Ophthalmology Support Services program helps eligible, enrolled patients who are taking Blenrep locate an eye care professional, schedule an eye care appointment, and provide reminders for scheduled eye care appointments. To learn more, call Together with GSK Oncology at 844-447-5662.

Zejula Quick Start and Bridge Programs

For patients experiencing delay in coverage at first dispense of Zejula (Quick Start) or coverage interruptions while already on treatment (Bridge), download and fill out the enrollment form, then fax to Together with GSK Oncology at 800-645-9043 to check for eligibility. Click here to access the form.

TABLE GlaxoSmithKline Oncology Drugs

Drugs
Indications
Patient support programs

Drug
Blenrep (belantamab mafodotin-blmf)
Indications
Treatment of adults with relapsed or refractory multiple myeloma who have received ≥4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
Patient support programs

Drug
Jemperli (dostarlimab-gxly) injection
Indications
Treatment of adult patients with mismatch repair deficient recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following treatment with a platinum-containing regimen, or solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options
Patient support programs


Zejula (niraparib) Indications

Maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy; treatment of adults with advanced ovarian, fallopian tube, or primary peritoneal cancer who have received ≥3 chemotherapy regimens and whose cancer is associated with homologous recombination deficiency–positive status, defined by deleterious or suspected deleterious BRCA mutation, or genomic instability, and whose disease progressed more than 6 months after responding to the last platinum-based chemotherapy

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)